成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> ACS Applied Bio Materials >>article
ACS Applied Bio Materials

ACS Applied Bio Materials

IF: 4.59
Download PDF

Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis.

Published:11 May 2015 DOI: 10.1371/journal.pone.0126704 PMID: 25961824
Shuyan Gu,?Jihao Shi,?Zhiliu Tang,?Monika Sawhney,?Huimei Hu,?Lizheng Shi,?Vivian Fonseca,?Hengjin Dong

Abstract

Background: Metformin is the first-line oral hypoglycemic agent for type 2 diabetes mellitus recommended by international guidelines. However, little information exists comparing it with acarbose which is also commonly used in China. This study expanded knowledge by combining direct and indirect evidence to ascertain the glucose lowering effects of both drugs.

Methods: PubMed (1980- December 2013) and China National Knowledge Infrastructure databases (1994-January 2014) were systematically searched for eligible randomized controlled trials from Chinese and English literatures. Meta-analysis was conducted to estimate the glucose lowering effects of metformin vs. acarbose, or either of them vs. common comparators (placebo or sulphonylureas), using random- and fixed-effect models. Bucher method with indirect treatment comparison calculator was applied to convert the summary estimates from the meta-analyses into weighted-mean-difference (WMD) and 95% confidence intervals (CIs) to represent the comparative efficacy between metformin and acarbose.

Results: A total of 75 studies were included in the analysis. In direct comparison (8 trials), metformin reduced glycosylated hemoglobin (HbA1c) by 0.06% more than acarbose, with no significant difference (WMD,-0.06%; 95% CI, -0.32% to 0.20%). In indirect comparisons (67 trials), by using placebo and sulphonylureas as common comparators, metformin achieved significant HbA1c reduction than acarbose, by -0.38% (WMD,-0.38%, 95% CI, -0.736% to -0.024%) and -0.34% (WMD, -0.34%, 95% CI, -0.651% to -0.029%) respectively.

Conclusion: The glucose lowering effects of metformin monotherapy and acarbose monotherapy are the same by direct comparison, while metformin is a little better by indirect comparison. This implies that the effect of metformin is at least as good as acarbose's.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Acarbose 56180-94-0 C25H43NO18 642 suppliers $6.00-$2245.70
Metformin 657-24-9 C4H11N5 179 suppliers $100.00-$681.08

Similar articles

IF:1.2

Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus.

Pakistan Journal of Medical Sciences Amir Ziaee, Neda Esmailzadehha,etc Published: 1 May 2017
IF:13

Linagliptin: in type 2 diabetes mellitus.

Drugs Lesley J Scott,etc Published: 26 March 2011
IF:13

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Drugs Greg L Plosker,etc Published: 3 December 2012